LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hello fellow warriors! Research really took a holiday this past week! But I did find something interesting for a short read. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.
​

Clinical Research

• Phase 1 and 2 Trials: Bipolar Androgen Therapy (BAT)Bipolar Androgen Therapy (BAT) is a paradoxical treatment strategy for metastatic androgen pathway modulation–resistant prostate cancer that replaces continuous androgen suppression with cyclical, supraphysiologic testosterone exposure.Clinical data from multiple prospective trials, including the Phase 1 COSMYC trial and the Phase 2 WOMBAT study, show that BAT produces PSA50 responses in approximately 30–40% of asymptomatic patients with low- to intermediate-burden disease. Research into biomarkers has identified that patients with AR amplification and pathogenic TP53 mutations constitute a high-response subgroup, achieving a PSA50 rate of roughly 70%. While the therapy is associated with improved quality of life and energy, there remains an approximate 10% risk of disease acceleration, which is why it is currently restricted to minimally symptomatic patients. Future developments are focused on making BAT more tunable through alternative cycle lengths or the use of oral, short-half-life AR agonists.​
  ​

Preclinical Research & Reviews

• CEASAR Study: Low 10-Year Prostate Cancer Mortality Across All Treatments for Localized Prostate Cancer
  ​A long-term follow-up from the observational CEASAR study reveals that ten years after diagnosis, most men with localized prostate cancer are far more likely to die from other causes than from their cancer. For patients with a favorable prognosis, the 10-year cumulative incidence of prostate cancer-specific mortality was exceptionally low, reaching no more than 1.5% across all management strategies, including surgery, radiation, and active surveillance. Although surgery appeared to be associated with lower all-cause mortality, this is likely due to selection bias, as men chosen for radical prostatectomy tend to be younger and healthier than those receiving other treatments. These results, which align with the 15-year data from the ProtecT randomized trial, suggest that the choice of treatment for localized disease should be guided by individual values, comorbidities, and tolerance for side effects rather than expected differences in survival only.​

​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max